Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 15, 2023

Pembrolizumab Plus Chemotherapy as a First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
J. Clin. Oncol 2023 Nov 01;[EPub Ahead of Print], BJ Monk, N Colombo, KS Tewari, C Dubot, MV Caceres, K Hasegawa, R Shapira-Frommer, P Salman, E Yañez, M Gümüş, M Olivera Hurtado de Mendoza, V Samouëlian, V Castonguay, A Arkhipov, C Tekin, K Li, SM Keefe, D Lorusso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading